| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Co-president | Director
2 companies
Jeffrey J Kraws is Director at TOVX, with reported holdings spanning 2 companies. Jeffrey J Kraws's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $44K at current prices.
Jeffrey J Kraws's largest disclosed position is in TOVX as Director, worth about $43K.
Jeffrey J Kraws has 19 Form 4 filings on record from December 2015 to January 2026, across 2 companies: Director at Theriva Biologics (TOVX), 2015–2026; Co-president at Catheter Precision (VTAK), 2019–2020.
The 21 reported transactions were 12 option or other derivative awards, 3 open-market purchases, 2 tax withholdings and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $8K and 2 sales worth about $90K.
The largest open-market purchase was 10,000 shares of VTAK at an average $0.46 on May 22, 2020, about $5K.
The largest open-market sale was 18,021 shares of VTAK at an average $3.08 on June 13, 2019, about $55K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2020 | VTAK Catheter Precision, Inc. | Co-president | Buy | 10,000 | $0.35 | $3,500.00 | +8.1% | |
| May 22, 2020 | VTAK Catheter Precision, Inc. | Co-president | Buy | 10,000 | $0.46 | $4,600.00 | +8.8% | |
| Jul 18, 2019 | VTAK Catheter Precision, Inc. | Co-president | Sell | 11,930 | $2.93 | $34,971.60 | -7.3% | |
| Jun 13, 2019 | VTAK Catheter Precision, Inc. | Co-president | Sell | 18,021 | $3.08 | $55,438.00 | -9.9% |